New immune cell therapy for hard-to-treat T-cell blood cancers

Plain-English translation of NCT06316427 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing CD7 CAR T-cell therapy, a personalized immune cell treatment for patients whose T-cell blood cancers have stopped responding to standard chemotherapy or other treatments. Researchers will use your own immune cells, or cells from a donor, and reprogram them in the lab to recognize and attack cancer cells. The trial will measure both how safe this treatment is and how well it works.

Many patients with aggressive T-cell blood cancers run out of treatment options when their cancer stops responding to chemotherapy or other standard therapies. This medication offers a new approach by harnessing the patient's own immune system to fight the cancer, potentially helping people who have very limited options otherwise.

Do you qualify?

You likely qualify if…

you have been diagnosed with a T-cell blood cancer (such as T-cell acute lymphoblastic leukemia or T-cell lymphoma) that has come back or stopped responding to standard treatments
your cancer cells show a specific marker called CD7 on their surface, confirmed by lab testing
you are between 1 and 70 years old
you are well enough to participate, as determined by your doctor (with a life expectancy of at least 60 days)
you have tried all standard treatment options and have no other available treatments

You likely don't qualify if…

you have an active, uncontrolled infection (including hepatitis B, hepatitis C, HIV, or other serious infections)
you have severe heart failure, serious breathing problems, or uncontrolled high blood pressure in the brain
you have another type of cancer in addition to your T-cell malignancy
you are pregnant, breastfeeding, or have severe kidney or liver problems
you have received an organ transplant

What participation looks like

If you qualify, doctors will either collect your own immune cells, use cells from a previous stem cell transplant donor, or obtain cells from a new donor—whichever is best for your situation. These cells will be sent to a lab where they are modified to recognize and attack your cancer. You will then receive the reprogrammed cells back through an infusion. You'll be closely monitored for safety over at least 3 months to see how well the treatment works and to watch for any side effects.

New immune cell therapy for hard-to-treat T-cell blood cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(4 sites)